Press Releases

Catalent Licenses Innovative Taste-Masking Technology for Bitter Drugs Following R&D Collaboration with New Jersey Institute of Technology

SOMERSET, N.J.--(BUSINESS WIRE)-- Following a successful research collaboration, Catalent Pharma Solutions announces that it has taken an exclusive license to innovative taste-masking technology developed by the New Jersey Institute of Technology (NJIT). The technology has been developed to mask the most challenging, unpleasant and bitter tasting pharmaceutical active ingredients.

Under the terms of the license, Catalent will complete transfer of the technology into its world class, cGMP facilities to support manufacture of novel dosage forms such as its Zydis® fast dissolve platform. It is expected that the taste-masking technology will be effective for developing a wide variety of formulations including granules/sachets, sprinkles, chewables, effervescent and oral dispersible tablets.

“Taste masking of fine drug particles has remained a technical challenge for formulators,” said Dr. Rajesh Davé, Distinguished Professor and Principal Investigator at NJIT. “Through funding from Catalent, we have been able to leverage our expertise to innovate technology and processes that allow for these materials to be cost effectively coated and taste-masked.”

Kurt Nielsen, Ph.D., Catalent’s Senior Vice President of Research and Development, commented, “Dr. Davé and his group at NJIT are leaders in pharmaceutical particle engineering. The unique approach to API coating is a perfect complement to Catalent’s extensive dose form capabilities and will facilitate formulation of the most difficult-to-taste-mask actives. Catalent has already produced the first feasibility samples, which have exceeded our expectations. This efficient and versatile taste-masking technology will allow development of new dosage forms delivering significant advantages to our customers and benefits to patients and consumers in global markets.”

About Catalent

Catalent Pharma Solutions is the global leader in development solutions and advanced drug delivery technologies, providing world-wide clinical and commercial supply capabilities for drugs, biologics and consumer health products. With over 75 years serving the industry, Catalent has proven expertise in bringing more customer products to market faster, enhancing product performance and ensuring reliable product supply. Catalent employs approximately 9,000 people, including over 1,000 scientists, at nearly 30 facilities across 5 continents and generates more than $1.6 billion in annual revenue. Catalent is headquartered in Somerset, N.J. For more information, visit

more products. better treatments. reliably supplied.™

About New Jersey Institute of Technology

NJIT, New Jersey's science and technology university, enrolls more than 9,558 students pursuing bachelor's, master's and doctoral degrees in 120 programs. The university consists of six colleges: Newark College of Engineering, College of Architecture and Design, College of Science and Liberal Arts, School of Management, College of Computing Sciences and Albert Dorman Honors College. U.S. News & World Report's 2012 Annual Guide to America's Best Colleges ranked NJIT in the top tier of national research universities. NJIT is internationally recognized for being at the edge in knowledge in architecture, applied mathematics, wireless communications and networking, solar physics, advanced engineered particulate materials, nanotechnology, neural engineering and e-learning. Many courses and certificate programs, as well as graduate degrees, are available online through the Division of Continuing Professional Education.

Patricia A. McGee, +1-732-537-6407
Chris Halling, +44 (0) 7580 41073

Source: Catalent Pharma Solutions